Other Events ·
On September 8, 2026, Monte Rosa Therapeutics announced that collaborator Novartis initiated a Phase 2 clinical study…
GLUEMonte Rosa Therapeutics, Inc.
On September 8, 2026, Monte Rosa Therapeutics announced that collaborator Novartis initiated a Phase 2 clinical study for MRT-6160 (DDY391) in participants with Sjögren’s disease. This event triggered a $50 million milestone payment from Novartis to Monte Rosa under their global exclusive license agreement. The company remains eligible for up to $2.1 billion in additional development, regulatory, and sales milestones. Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degrader medicines.